With over-diagnosis and over-treatment of indolent prostate cancer, non-invasive screening tools that predict low-grade (¼ Gleason score 6, GS 6) from high-grade (¼GS 7) prostate cancer (PCa) will play a significant role in the treatment decision process. Recently, we demonstrated that a urine exosome gene expression assay (ExoDx Prostate (IntelliScore) (EPI)) was able to discriminate high-grade (¼GS 7) from low-grade (GS 6) and benign disease biopsy outcomes, thereby improving the identification of men with higher-grade PCa, potentially reducing the number of unnecessary biopsies. In a parallel study, we had also shown that EPI scores were associated with pathologic stage (PS) and radical prostatectomy Gleason score (RP-GS). We now sought to expand these results and further examine outcomes from men enrolled in the biopsy validation trial who had selected surgery.
INTRODUCTION AND OBJECTIVES: Distinguishing between low-grade and high-grade prostate cancer (PCa) as detected by biopsy results is very important, not only for diagnosis, but also for monitoring patients on active surveillance. However, biopsy results may underestimate the actual grade of the PCa when prostatectomy is performed. We developed an algorithm to predict the presence of high-grade PCa on biopsy using cell-free RNA (cfRNA) levels of UAP1, PDLIM5, IMPDH2, HSPD1, PCA3, PSA, TMPRSS2, AR, PTEN, and ERG genes in both urine and peripheral blood plasma. We show that this algorithm is highly reliable in predicting high grade (Gleason 3+4) PCa based on biopsy results in 489 patients. We also show in a prospective study that this algorithm is very reliable in an additional 300 patients who underwent prostatectomy.
METHODS: Levels of cfRNA in urine and plasma from 489 patients were quantified using real-time PCR. Patients were selected randomly based on clinical suspicion of the presence of PCa. In addition, urine and blood samples from 300 patients were collected and tested prior to performing prostatectomy.
RESULTS: Biopsy results from the first group showed Gleason 3+3 PCa in 103 patients (21%) and Gleason 3+4 PCa in 147 patients (30%). Patients with Gleason 4+3 were 55 (11%). Patients with Gleason 3+3 were grouped with non-cancer patients and considered as one group.We used a simple algorithm incorporating prostate size, age, serum PSA along with 5 biomarkers to divide patients into two separate groups as low-risk and high-risk. Then each group was further refined and separated using a second algorithm implementing the rest of the biomarkers along with prior history of prostate biopsy. This resulted in high accuracy in predicting the presence of high-grade PCa with sensitivity between 97% and 86% and a specificity between 36% and 57%, dependent on which cut-off point was used. Sensitivity for predicting PCa Gleason 4+3 was between 99% and 96% and specificity between 37% and 59%. Diagnosis of Gleason 3+4 was missed in 1% to 3% of tested patients and of Gleason 4+3 in 0.2% to 1%. Testing the additional 300 samples with prostatectomy data demonstrated accurate prediction of cancer missing only 2.6% to 7% of Gleason 3+4 and 1 to 3% of 4+3, dependent on which cut-off point is used.
CONCLUSIONS: Taking advantage of urine and plasma biomarkers as well as serum PSA and prostate size and prior history of biopsy, we were able to predict high grade prostate cancer with negative predictive value (NPV) of 97% to 90% for Gleason 3+4 and between 99% to 98% for Gleason 4+3. Furthermore, this test was further proved to be highly sensitive as confirmed by prostatectomy data.
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MP33-07 CHARACTERIZING LOCAL RECURRENCE AFTER RADICAL PROSTATECTOMY USING MR-TARGETED BIOPSY
Shawn Mendonca*, John Graham, Daniel Sjoberg, Melissa Assel, Jonathan Coleman, Behfar Ehdaie, New York, NY INTRODUCTION AND OBJECTIVES: In patients with biochemical recurrence (BCR) after radical prostatectomy (RP), MRI is being increasingly utilized as the modality to visualize local recurrence. We aim to identify the role of MR-targeted biopsy to detect local recurrence in patients with rising PSA after RP. In addition, we evaluated clinical and pathologic characteristics to predict local recurrence using MR-targeted biopsy.
METHODS: In a retrospective study, we identified men with rising PSA who underwent MR-targeted biopsy for local recurrence between June 2012 and June 2016. We collected data on RP pathology, pre-RP PSA, and MRI-assessed suspicion for prostate cancer scored on a standardized 5-point scale. The detection rate of prostate cancer was estimated for different MRI levels of suspicion and all patients underwent an MR-targeted biopsy. In addition, using Wilcoxon rank sum test, and Fisher's exact test, we investigated whether RP pathologic characteristics were predictive of prostate cancer on biopsy.
RESULTS: A total of 54 post-RP patients underwent MR-targeted biopsy for rising PSA. 25 (46%) patients had a positive biopsy identifying prostate cancer and 29 (54%) had a negative biopsy. In Table 1 , MRI lesion score was the only clinical variable that was significantly associated (p¼0.010) with improved detection of prostate cancer on biopsy. Additionally, subsequent increases in the MRI lesion Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e419
